HydroCision is the leading developer, manufacturer and marketer of fluidjet-based surgical tools that are the foundation of a new surgical modality - 'hydrosurgery'. Hydrosurgery improves patient care by selectively removing tissue, minimizing collateral damage and bleeding, and promoting the healing process. HydroCision believes its proprietary fluidjet technology platform is the basis of a new surgical modality because of its compelling features and versatility. Incorporated in 1996, the company continues to develop a broad range of fluidjet-based devices to meet the needs of multiple specialties. Current investors include Zero Stage Capital, Newbury Ventures, and Oxford Bioscience Partners.